Rafferty Asset Management
PHAT icon

Rafferty Asset Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Rafferty Asset Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$138K Buy
+12,756
New +$146K ﹤0.01% 1122
2026
Q1 		– Sell
-13,855
Closed -$230K – 1127
2025
Q4 		$230K Buy
+13,855
New +$198K ﹤0.01% 1060
2025
Q1 		– Sell
-11,113
Closed -$90.2K – 1130
2024
Q4 		$90.2K Buy
+11,113
New +$138K ﹤0.01% 1128

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Rafferty Asset Management's PHAT Position: Q2 2026 in Review

Rafferty Asset Management opened a new position in Phathom Pharmaceuticals (PHAT) in Q2 2026: 12,756 shares worth $138K. The stake represents ﹤0.01% of the portfolio and ranks #1122 among its holdings. This is a return to the name: Rafferty Asset Management previously reported a position in PHAT as recently as Q4 2025.

Rafferty Asset Management first reported a position in PHAT in Q4 2024 and has held it in 3 quarters since. The position peaked at $230K in Q4 2025. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Rafferty Asset Management held 12,756 shares of Phathom Pharmaceuticals worth $138K as of Q2 2026.
  • Phathom Pharmaceuticals was a new Rafferty Asset Management position in Q2 2026.
  • Phathom Pharmaceuticals made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #1122 holding.
  • Rafferty Asset Management first reported a position in Phathom Pharmaceuticals in Q4 2024 and has held it in 3 quarters since.
  • Rafferty Asset Management's Phathom Pharmaceuticals position peaked at $230K in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.